<?xml version='1.0' encoding='utf-8'?>
<document id="28403692"><sentence text="Severe hypokalemia due to a possible drug-drug interaction between vinblastine and antiretrovirals in a HIV-infected patient with Hodgkin's lymphoma."><entity charOffset="67-78" id="DDI-PubMed.28403692.s1.e0" text="vinblastine" /></sentence><sentence text="A 60-year-old HIV-1 infected woman on antiretroviral therapy (emtricitabine/tenofovir, and ritonavir-boosted atazanavir) developed Hodgkin's lymphoma"><entity charOffset="62-75" id="DDI-PubMed.28403692.s2.e0" text="emtricitabine" /><entity charOffset="76-85" id="DDI-PubMed.28403692.s2.e1" text="tenofovir" /><entity charOffset="91-100" id="DDI-PubMed.28403692.s2.e2" text="ritonavir" /><entity charOffset="109-119" id="DDI-PubMed.28403692.s2.e3" text="atazanavir" /><pair ddi="false" e1="DDI-PubMed.28403692.s2.e0" e2="DDI-PubMed.28403692.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28403692.s2.e0" e2="DDI-PubMed.28403692.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28403692.s2.e0" e2="DDI-PubMed.28403692.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28403692.s2.e0" e2="DDI-PubMed.28403692.s2.e3" /><pair ddi="false" e1="DDI-PubMed.28403692.s2.e1" e2="DDI-PubMed.28403692.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28403692.s2.e1" e2="DDI-PubMed.28403692.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28403692.s2.e1" e2="DDI-PubMed.28403692.s2.e3" /><pair ddi="false" e1="DDI-PubMed.28403692.s2.e2" e2="DDI-PubMed.28403692.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28403692.s2.e2" e2="DDI-PubMed.28403692.s2.e3" /></sentence><sentence text=" The patient initiated ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) chemotherapy and presented with neutropenia and severe hypokalemia"><entity charOffset="23-27" id="DDI-PubMed.28403692.s3.e0" text="ABVD" /><entity charOffset="29-40" id="DDI-PubMed.28403692.s3.e1" text="doxorubicin" /><entity charOffset="42-51" id="DDI-PubMed.28403692.s3.e2" text="bleomycin" /><entity charOffset="53-64" id="DDI-PubMed.28403692.s3.e3" text="vinblastine" /><entity charOffset="69-80" id="DDI-PubMed.28403692.s3.e4" text="dacarbazine" /><pair ddi="false" e1="DDI-PubMed.28403692.s3.e0" e2="DDI-PubMed.28403692.s3.e0" /><pair ddi="false" e1="DDI-PubMed.28403692.s3.e0" e2="DDI-PubMed.28403692.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28403692.s3.e0" e2="DDI-PubMed.28403692.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28403692.s3.e0" e2="DDI-PubMed.28403692.s3.e3" /><pair ddi="false" e1="DDI-PubMed.28403692.s3.e0" e2="DDI-PubMed.28403692.s3.e4" /><pair ddi="false" e1="DDI-PubMed.28403692.s3.e1" e2="DDI-PubMed.28403692.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28403692.s3.e1" e2="DDI-PubMed.28403692.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28403692.s3.e1" e2="DDI-PubMed.28403692.s3.e3" /><pair ddi="false" e1="DDI-PubMed.28403692.s3.e1" e2="DDI-PubMed.28403692.s3.e4" /><pair ddi="false" e1="DDI-PubMed.28403692.s3.e2" e2="DDI-PubMed.28403692.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28403692.s3.e2" e2="DDI-PubMed.28403692.s3.e3" /><pair ddi="false" e1="DDI-PubMed.28403692.s3.e2" e2="DDI-PubMed.28403692.s3.e4" /><pair ddi="false" e1="DDI-PubMed.28403692.s3.e3" e2="DDI-PubMed.28403692.s3.e3" /><pair ddi="false" e1="DDI-PubMed.28403692.s3.e3" e2="DDI-PubMed.28403692.s3.e4" /></sentence><sentence text=" Hypokalemia was considered as part of a proximal tubular renal dysfunction, and other causes of hypokalemia were excluded" /><sentence text=" Due to suspicion of drug--drug interactions between antiretrovirals and vinblastine, ritonavir-boosted atazanavir was switched to dolutegravir and the patient continued emtricitabine/tenofovir"><entity charOffset="73-84" id="DDI-PubMed.28403692.s5.e0" text="vinblastine" /><entity charOffset="86-95" id="DDI-PubMed.28403692.s5.e1" text="ritonavir" /><entity charOffset="104-114" id="DDI-PubMed.28403692.s5.e2" text="atazanavir" /><entity charOffset="131-143" id="DDI-PubMed.28403692.s5.e3" text="dolutegravir" /><entity charOffset="170-183" id="DDI-PubMed.28403692.s5.e4" text="emtricitabine" /><entity charOffset="184-193" id="DDI-PubMed.28403692.s5.e5" text="tenofovir" /><pair ddi="false" e1="DDI-PubMed.28403692.s5.e0" e2="DDI-PubMed.28403692.s5.e0" /><pair ddi="false" e1="DDI-PubMed.28403692.s5.e0" e2="DDI-PubMed.28403692.s5.e1" /><pair ddi="false" e1="DDI-PubMed.28403692.s5.e0" e2="DDI-PubMed.28403692.s5.e2" /><pair ddi="false" e1="DDI-PubMed.28403692.s5.e0" e2="DDI-PubMed.28403692.s5.e3" /><pair ddi="false" e1="DDI-PubMed.28403692.s5.e0" e2="DDI-PubMed.28403692.s5.e4" /><pair ddi="false" e1="DDI-PubMed.28403692.s5.e0" e2="DDI-PubMed.28403692.s5.e5" /><pair ddi="false" e1="DDI-PubMed.28403692.s5.e1" e2="DDI-PubMed.28403692.s5.e1" /><pair ddi="false" e1="DDI-PubMed.28403692.s5.e1" e2="DDI-PubMed.28403692.s5.e2" /><pair ddi="false" e1="DDI-PubMed.28403692.s5.e1" e2="DDI-PubMed.28403692.s5.e3" /><pair ddi="false" e1="DDI-PubMed.28403692.s5.e1" e2="DDI-PubMed.28403692.s5.e4" /><pair ddi="false" e1="DDI-PubMed.28403692.s5.e1" e2="DDI-PubMed.28403692.s5.e5" /><pair ddi="false" e1="DDI-PubMed.28403692.s5.e2" e2="DDI-PubMed.28403692.s5.e2" /><pair ddi="false" e1="DDI-PubMed.28403692.s5.e2" e2="DDI-PubMed.28403692.s5.e3" /><pair ddi="false" e1="DDI-PubMed.28403692.s5.e2" e2="DDI-PubMed.28403692.s5.e4" /><pair ddi="false" e1="DDI-PubMed.28403692.s5.e2" e2="DDI-PubMed.28403692.s5.e5" /><pair ddi="false" e1="DDI-PubMed.28403692.s5.e3" e2="DDI-PubMed.28403692.s5.e3" /><pair ddi="false" e1="DDI-PubMed.28403692.s5.e3" e2="DDI-PubMed.28403692.s5.e4" /><pair ddi="false" e1="DDI-PubMed.28403692.s5.e3" e2="DDI-PubMed.28403692.s5.e5" /><pair ddi="false" e1="DDI-PubMed.28403692.s5.e4" e2="DDI-PubMed.28403692.s5.e4" /><pair ddi="false" e1="DDI-PubMed.28403692.s5.e4" e2="DDI-PubMed.28403692.s5.e5" /></sentence><sentence text=" In the subsequent ABVD cycles, no neutropenia or hypokalemia were observed"><entity charOffset="19-27" id="DDI-PubMed.28403692.s6.e0" text="ABVD" /></sentence><sentence text=" Vinblastine is metabolized by the hepatic P450 cytochrome isoenzyme CYP3A4, therefore, concomitant administration with protease inhibitors may increase plasma levels of vinblastine"><entity charOffset="1-12" id="DDI-PubMed.28403692.s7.e0" text="Vinblastine" /><entity charOffset="170-181" id="DDI-PubMed.28403692.s7.e1" text="vinblastine" /><pair ddi="false" e1="DDI-PubMed.28403692.s7.e0" e2="DDI-PubMed.28403692.s7.e0" /><pair ddi="false" e1="DDI-PubMed.28403692.s7.e0" e2="DDI-PubMed.28403692.s7.e1" /></sentence><sentence text=" Vinblastine is also a substrate and inhibitor of multidrug resistance-associated protein 2 (MRP2) transporter in the proximal renal tubule"><entity charOffset="1-12" id="DDI-PubMed.28403692.s8.e0" text="Vinblastine" /></sentence><sentence text=" Inhibition of this renal transporter could increase tenofovir renal toxicity"><entity charOffset="53-62" id="DDI-PubMed.28403692.s9.e0" text="tenofovir" /></sentence><sentence text=" Our hypothesis is that the hypokalemia could be a result of a tenofovir-mediated tubular damage triggered by the increased vinblastine serum levels secondary to a CYP3A4 inhibition by ritonavir"><entity charOffset="63-72" id="DDI-PubMed.28403692.s10.e0" text="tenofovir" /><entity charOffset="124-135" id="DDI-PubMed.28403692.s10.e1" text="vinblastine" /><entity charOffset="185-194" id="DDI-PubMed.28403692.s10.e2" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.28403692.s10.e0" e2="DDI-PubMed.28403692.s10.e0" /><pair ddi="false" e1="DDI-PubMed.28403692.s10.e0" e2="DDI-PubMed.28403692.s10.e1" /><pair ddi="false" e1="DDI-PubMed.28403692.s10.e0" e2="DDI-PubMed.28403692.s10.e2" /><pair ddi="false" e1="DDI-PubMed.28403692.s10.e1" e2="DDI-PubMed.28403692.s10.e1" /><pair ddi="false" e1="DDI-PubMed.28403692.s10.e1" e2="DDI-PubMed.28403692.s10.e2" /></sentence><sentence text=" To the best of our knowledge, this is the first report of severe hypokalemia and proximal tubular renal dysfunction as a result of a possible drug-drug interaction between vinblastine, tenofovir and ritonavir-boosted atazanavir"><entity charOffset="173-184" id="DDI-PubMed.28403692.s11.e0" text="vinblastine" /><entity charOffset="186-195" id="DDI-PubMed.28403692.s11.e1" text="tenofovir" /><entity charOffset="200-209" id="DDI-PubMed.28403692.s11.e2" text="ritonavir" /><entity charOffset="218-228" id="DDI-PubMed.28403692.s11.e3" text="atazanavir" /><pair ddi="false" e1="DDI-PubMed.28403692.s11.e0" e2="DDI-PubMed.28403692.s11.e0" /><pair ddi="false" e1="DDI-PubMed.28403692.s11.e0" e2="DDI-PubMed.28403692.s11.e1" /><pair ddi="false" e1="DDI-PubMed.28403692.s11.e0" e2="DDI-PubMed.28403692.s11.e2" /><pair ddi="false" e1="DDI-PubMed.28403692.s11.e0" e2="DDI-PubMed.28403692.s11.e3" /><pair ddi="false" e1="DDI-PubMed.28403692.s11.e1" e2="DDI-PubMed.28403692.s11.e1" /><pair ddi="false" e1="DDI-PubMed.28403692.s11.e1" e2="DDI-PubMed.28403692.s11.e2" /><pair ddi="false" e1="DDI-PubMed.28403692.s11.e1" e2="DDI-PubMed.28403692.s11.e3" /><pair ddi="false" e1="DDI-PubMed.28403692.s11.e2" e2="DDI-PubMed.28403692.s11.e2" /><pair ddi="false" e1="DDI-PubMed.28403692.s11.e2" e2="DDI-PubMed.28403692.s11.e3" /></sentence><sentence text="" /></document>